bumetanide has been researched along with Huntington Disease in 1 studies
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dargaei, Z | 1 |
| Bang, JY | 1 |
| Mahadevan, V | 1 |
| Khademullah, CS | 1 |
| Bedard, S | 1 |
| Parfitt, GM | 1 |
| Kim, JC | 1 |
| Woodin, MA | 1 |
1 other study available for bumetanide and Huntington Disease
| Article | Year |
|---|---|
Restoring GABAergic inhibition rescues memory deficits in a Huntington's disease mouse model.
Topics: Animals; Bumetanide; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Hippocampus; Humans; H | 2018 |